Treatment of progressive fibrosing interstitial lung diseases: a milestone in the management of interstitial lung diseases

Fibrosing ILDs can develop a progressive phenotype and are described under the terminology PF-ILDs. Due to commonalities with IPF, the potential efficacy and tolerability of antifibrotic drugs pirfenidone and nintedanib are currently evaluated in PF-ILDs. http://bit.ly/2koL0A4

Detalles Bibliográficos
Autor principal: Cottin, Vincent
Formato: Online Artículo Texto
Lenguaje:English
Publicado: European Respiratory Society 2019
Materias:
Editorial
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9488849/
https://www.ncbi.nlm.nih.gov/pubmed/31578213
http://dx.doi.org/10.1183/16000617.0109-2019
Descripción
Sumario:Fibrosing ILDs can develop a progressive phenotype and are described under the terminology PF-ILDs. Due to commonalities with IPF, the potential efficacy and tolerability of antifibrotic drugs pirfenidone and nintedanib are currently evaluated in PF-ILDs. http://bit.ly/2koL0A4

Ejemplares similares